Evidence map›Paper›PMID 30320491›Full record

ArticleJournal of cellular and molecular medicine2018

PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.

Xianwen Yang, Yun Tan, Ping Wang, Hui Zhang, Ming Zhao, Xujie Zhao, Kankan Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xianwen YangState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yun TanState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ping WangState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hui ZhangState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ming ZhaoState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xujie ZhaoState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Kankan WangState Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-7198-2134
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The PML-RARα fusion gene, generated by the t(15;17) chromosome translocation, is regarded as the initiating factor of acute promyelocytic leukaemia (APL). In addition to the well-known effects on blocking myeloid differentiation at the promyelocytic stage, promyelocytic leukaemia-retinoic acid receptor α (PML-RARα) has also been reported to interfere with multiple differentiation processes, including erythroid differentiation. However, the detailed molecular mechanism by which PML-RARα impairs erythropoiesis has not yet been fully addressed. By chromatin immunoprecipitation-PCR assay, we found that PML-RARα bound to the distal promoter region of LMO2 (LIM-only protein 2), a critical erythroid-specific transcription factor. Luciferase reporter assays and qRT-PCR results demonstrated that PML-RARα down-regulated the expression of the LMO2 distal transcript through transrepressing its promoter activity. Analysis of gene expression profiling data from large cohorts of acute myeloid leukaemia (AML) patients confirmed that LMO2 expressed at a markedly lower level in APL patients in comparison to non-APL AML patients. Further flow cytometry analysis demonstrated that PML-RARα inhibited erythropoietin-induced erythroid differentiation by down-regulating LMO2 expression. Our findings reveal a previously unidentified mechanism, by which PML-RARα interferes with erythropoiesis through directly targeting and transrepressing LMO2 expression in the development of APL.

Indexed as

Adaptor Proteins, Signal TransducingCell DifferentiationCell Line, TumorErythropoiesisFemaleGene Expression ProfilingHumansLeukemia, Myeloid, AcuteLeukemia, Promyelocytic, AcuteLIM Domain ProteinsMaleOncogene Proteins, FusionPromoter Regions, GeneticProtein BindingProto-Oncogene ProteinsTranslocation, GeneticAdaptor Proteins, Signal TransducingLIM Domain ProteinsLMO2 protein, humanOncogene Proteins, Fusionpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinProto-Oncogene Proteinsacute promyelocytic leukaemiaerythropoiesisLMO2PML-RARα

Identifiers

PMID30320491
PMCPMC6237603
OpenAlexW2897927480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.